Safety and Efficacy of Turoctocog Alfa in the Prevention and Treatment of Bleeding Episodes in Previously Treated Patients from China with Severe Hemophilia A: Results from the Guardian 7 Trial

References

• Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al. Guidelines for the management of hemophilia. Haemophilia. 2013;19(1):e1–47.
   PubMed Web of Science ®Google Scholar
• Melchiorre D, Manetti M, Matucci-Cerinic M. Pathophysiology of hemophilic arthropathy. J Clin Med. 2017;6(7):63. doi:10.3390/jcm6070063
   PubMed Web of Science ®Google Scholar
• Hartmann J, Croteau SE. 2017 Clinical trials update: innovations in hemophilia therapy. Am J Hematol. 2016;91(12):1252–1260. doi:10.1002/ajh.24543
   PubMed Web of Science ®Google Scholar
• Bertamino M, Riccardi F, Banov L, Svahn J, Molinari AC. Hemophilia care in the pediatric age. J Clin Med. 2017;6(5):54. doi:10.3390/jcm6050054
   PubMed Web of Science ®Google Scholar
• Arruda VR, Doshi BS, Samelson-Jones BJ. Emerging therapies for hemophilia: controversies and unanswered questions. F1000Res. 2018;7:F1000Faculty Rev–1489. doi:10.12688/f1000research.12491.1
   Google Scholar
• Poon MC, Luke KH. Haemophilia care in China: achievements of a decade of World Federation of Hemophilia treatment centre twinning activities. Haemophilia. 2008;14(5):879–888. doi:10.1111/j.1365-2516.2008.01821.x
   PubMed Web of Science ®Google Scholar
• Zhao H, Yang L, Long C, et al. Hemophilia care in China: review of care for 417 hemophilia patients from 11 treatment centers in Shanxi Province. Expert Rev Hematol. 2015;8(4):543–550. doi:10.1586/17474086.2015.1043263
   PubMed Web of Science ®Google Scholar
• Li C, Zhang X, Zhao Y, et al. Status and trend analysis of prophylactic usage of recombinant factor VIII in Chinese pediatric patients with hemophilia A: reCare - a retrospective, Phase IV, non-interventional study. Curr Med Res Opin. 2017;33(9):1571–1578. doi:10.1080/03007995.2017.1333489
   PubMed Web of Science ®Google Scholar
• Wu R, Luke KH. The benefit of low dose prophylaxis in the treatment of hemophilia: a focus on China. Expert Rev Hematol. 2017;10(11):995–1004. doi:10.1080/17474086.2017.1386096
   PubMed Web of Science ®Google Scholar
• Zhang L, Li H, Zhao H, Zhang X, Ji L, Yang R. Retrospective analysis of 1312 patients with haemophilia and related disorders in a single Chinese institute. Haemophilia. 2003;9(6):696–702. doi:10.1046/j.1351-8216.2003.00826.x
   PubMed Web of Science ®Google Scholar
• ClinicalTrials.gov. Interventional Studies of rFVIII for Haemophilia A in China (Clinicaltrials.gov search), 2019. Available from: https://clinicaltrials.gov/ct2/results?term=recombinant+FVIII&cond=Hemophilia+A&cntry=CN&age_v=&gndr=&type=Intr&rslt=&Search=Apply. Accessed September 2019.
   Google Scholar
• Thim L, Vandahl B, Karlsson J, et al. Purification and characterization of a new recombinant factor VIII (N8). Haemophilia. 2010;16(2):349–359. doi:10.1111/j.1365-2516.2009.02135.x
   PubMed Web of Science ®Google Scholar
• Ahmadian H, Hansen EB, Faber JH, et al. Molecular design and downstream processing of turoctocog alfa (NovoEight), a B-domain truncated factor VIII molecule. Blood Coagul Fibrinolysis. 2016;27(5):568–575. doi:10.1097/MBC.0000000000000477
   PubMed Web of Science ®Google Scholar
• Novo Nordisk. NovoEight (turoctocog alfa): summary of Product Characteristics, 2018. Available from: https://www.ema.europa.eu/en/documents/product-information/novoeight-epar-product-information_en.pdf. Accessed September 2019.
   Google Scholar
• Lentz SR, Janic D, Kavakli K, et al. Long-term safety and efficacy of turoctocog alfa in prophylaxis and treatment of bleeding episodes in severe haemophilia A: final results from the guardian 2 extension trial. Haemophilia. 2018;24(6):. doi:10.1111/hae.13617
   Web of Science ®Google Scholar
• Yaish H, Matsushita T, Belhani M, et al. Safety and efficacy of turoctocog alfa in the prevention and treatment of bleeds in previously untreated paediatric patients with severe haemophilia A: results from the guardian 4 multinational clinical trial. Haemophilia. 2020;26(1):64–72. doi:10.1111/hae.13883
   PubMed Web of Science ®Google Scholar
• Napolitano M, Nøhr AM. The Effect of Fluctuating Temperature on the Stability of Turoctocog Alfa for Hemophilia A. Drugs R D. 2019;19(4):381–390. doi:10.1007/s40268-019-00290-3
   PubMed Web of Science ®Google Scholar
• Tischer B, Marino R, Napolitano M. Patient preferences in the treatment of hemophilia A: impact of storage conditions on product choice. Patient Prefer Adherence. 2018;12:431–441. doi:10.2147/PPA.S151812
   PubMed Web of Science ®Google Scholar
• European Medicines Agency. Guideline on the clinical investigation of recombinant and human plasma-derived factor VIII products, 2018. Available from: https://www.ema.europa.eu/en/documents/scientific-guideline/guideline-clinical-investigation-recombinant-human-plasma-derived-factor-viii-products-revision-2_en.pdf. Accessed September 2019.
   Google Scholar
• World Medical Association. Declaration of Helsinki - Ethical Principles for Medical Research Involving Human Subjects. Last amended by the 59th WMA General Assembly, Seoul, Republic of Korea, 2008. Available from: https://www.wma.net/wp-content/uploads/2018/07/DoH-Oct2008.pdf. Accessed September 2019.
   Google Scholar
• International Conference on Harmonisation. ICH Harmonised Tripartite Guideline. Good Clinical Practice, 01-May-1996, Geneva, Switzerland; 1996. Available from: https://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E6/E6_R1_Guideline.pdf. Accessed September 2019.
   Google Scholar
• Blanchette VS, Key NS, Ljung LR, Manco-Johnson MJ, van den Berg HM, Srivastava A. Definitions in hemophilia: communication from the SSC of the ISTH. J Thromb Haemost. 2014;12(11):1935–1939. doi:10.1111/jth.12672
   PubMed Web of Science ®Google Scholar
• Li C, Zhang X, Zhao Y, et al. Long-term efficacy and safety of prophylaxis with recombinant factor VIII in Chinese pediatric patients with hemophilia A: a multi-center, retrospective, non-interventional, phase IV (ReCARE) study. Curr Med Res Opin. 2017;33(7):1223–1230. doi:10.1080/03007995.2017.1310720
   PubMed Web of Science ®Google Scholar
• Yao W, Xiao J, Cheng X, et al. The efficacy of recombinant FVIII low-dose prophylaxis in Chinese pediatric patients with severe hemophilia A: a retrospective analysis from the ReCARE study. Clin Appl Thromb Hemost. 2017;23(7):851–858. doi:10.1177/1076029616679507
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med. 2007;357(6):535–544. doi:10.1056/NEJMoa067659
   PubMed Web of Science ®Google Scholar
• Manco-Johnson MJ, Soucie JM, Gill JC. Prophylaxis usage, bleeding rates, and joint outcomes of hemophilia, 1999 to 2010: a surveillance project. Blood. 2017;129(17):2368–2374. doi:10.1182/blood-2016-02-683169
   PubMed Web of Science ®Google Scholar
• Zhao Y, Xiao J, Yang R, et al. Efficacy of standard prophylaxis versus on-demand treatment with Bayer's sucrose-formulated recombinant FVIII (rFVIII-FS) in Chinese children with severe hemophilia A. Pediatr Hematol Oncol. 2017;34(3):138–148. doi:10.1080/08880018.2017.1313921
   PubMed Web of Science ®Google Scholar
• Thrombosis and Hemostasis Group, Hematology Society of Chinese Medical Association, Hemophilia Treatment Center Collaborative Network of China. Consensus of Chinese expert on the diagnosis and treatment of hemophilia (version 2017). Zhonghua Xue Ye Xue Za Zhi. 2017;38(5):364–370. doi:10.3760/cma.j.issn.0253-2727.2017.05.002
   PubMedGoogle Scholar
• Lentz SR, Misgav M, Ozelo M, et al. Results from a large multinational clinical trial (guardian™1) using prophylactic treatment with turoctocog alfa in adolescent and adult patients with severe haemophilia A: safety and efficacy. Haemophilia. 2013;19(5):691–697. doi:10.1111/hae.12159
   PubMed Web of Science ®Google Scholar
• Kulkarni R, Karim FA, Glamocanin S, et al. Results from a large multinational clinical trial (guardian™3) using prophylactic treatment with turoctocog alfa in paediatric patients with severe haemophilia A: safety, efficacy and pharmacokinetics. Haemophilia. 2013;19(5):698–705. doi:10.1111/hae.12165
   PubMed Web of Science ®Google Scholar
• Shi J, Zhao Y, Wu J, Sun J, Wang L, Yang R. Safety and efficacy of a sucrose-formulated recombinant factor VIII product for the treatment of previously treated patients with haemophilia A in China. Haemophilia. 2007;13(4):351–356. doi:10.1111/j.1365-2516.2007.01472.x
   PubMed Web of Science ®Google Scholar
• Zhang L, Zhao Y, Sun J, Wang X, Yu M, Yang R. Clinical observation on safety and efficacy of a plasma- and albumin-free recombinant factor VIII for on-demand treatment of Chinese patients with haemophilia A. Haemophilia. 2011;17(2):191–195. doi:10.1111/j.1365-2516.2010.02395.x
   PubMed Web of Science ®Google Scholar
• Jiménez-Yuste V, Lejniece S, Klamroth R, et al. The pharmacokinetics of a B-domain truncated recombinant factor VIII, turoctocog alfa (NovoEight(R)), in patients with hemophilia A. J Thromb Haemost. 2015;13(3):370–379. doi:10.1111/jth.12816
   PubMed Web of Science ®Google Scholar
• Tiede A, Goldmann G, Miljic P, et al. Body mass index was found to be the best predictor for the pharmacokinetics of recombinant factor VIII. Haemophilia. 2018;24:215–216.
   Google Scholar
• Wyrwich KW, Krishnan S, Poon JL, et al. Interpreting important health-related quality of life change using the Haem-A-QoL. Haemophilia. 2015;21(5):578–584. doi:10.1111/hae.12642
   PubMed Web of Science ®Google Scholar
• Varaklioti A, Kontodimopoulos N, Niakas D, Kouramba A, Katsarou O. Health-related quality of life and association with arthropathy in Greek patients with hemophilia. Clin Appl Thromb Hemost. 2018;24(5):815–821. doi:10.1177/1076029617733041
   PubMed Web of Science ®Google Scholar